MG-ADL and QMG scores over time in patients with generalized myasthenia gravis: Post-hoc analysis of MycarinG and open-label studies

Important Information Related to Your Request:

The material below is provided in response to your specific search for information on UCBCOMPASS^® and may contain information that is not part of the FDA-approved Prescribing Information. UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please review the Full Prescribing Information.

The effect of rozanolixizumab-noli on MG-ADL and QMG scores over time was a post-hoc analysis, therefore results should be interpreted with caution.